Latest news with #Sigachi
Business Standard
4 days ago
- Business
- Business Standard
Sigachi Industries Achieves 46% EBITDA Growth and 25% Revenue Surge in FY25, Strengthens Market Leadership
VMPL Hyderabad (Telangana) [India], June 2: Sigachi Industries Ltd. (Sigachi), India's largest manufacturer of microcrystalline cellulose (MCC), has demonstrated robust financial performance in FY25 while setting the stage for aggressive future growth. With a strong EBITDA growth of 46.21% YoY to Rs1,120 million and a revenue surge of 25.42% to Rs5,003 million, Sigachi is positioning itself for a 25% CAGR through FY28, driven by capacity expansions, market diversification, and API development. Commenting on the company's performance in FY25 and its projected trajectory, Mr. Amit Raj Sinha, MD & CEO, Sigachi Industries stated: "FY25 has been a transformative year for Sigachi, marked by robust financial outcomes and strategic expansions across excipients and APIs. With our Hyderabad API R & D centre going live in Q1 FY26, regulatory approvals flowing in, and global market penetration deepening, we are positioned for sustainable high-margin growth. Our 36-year legacy and diversified portfolio give us an unmatched advantage to scale operations globally while safeguarding profitability." Sigachi has created a strategic growth roadmap through to FY 2028 revolving around: * API Expansion: With the integration of Trimax Biosciences, the company is scaling its advanced intermediate and API portfolio. Plans include filing six additional European CEP dossiers, expanding regulatory approvals, and ramping up capacity utilisation. * Market Diversification: Sigachi is expanding its footprint beyond India, the U.S., and Europe by aggressively entering Latin America, Southeast Asia, and the Middle East through new distribution partnerships and turnkey O & M contracts. * Excipient Capacity Growth: Newly commissioned MCC in Jhagadia and Dahej and CCS project expansions will unlock an additional 8,800 MTPA, fuelling year-over-year revenue gains of 20%-30% in excipients. Additionally, new product launches in Pharma Coatings are expected to be the new growth drivers over the next two years * Operational Efficiencies: Digital analytics, lean processing, and energy efficiency initiatives are expected to trim operating costs by 100-150 basis points annually, preserving EBITDA margins while mitigating raw-material volatility. * O & M Services Expansion: The company is scaling its outsourced plant-management contracts, which already contribute 10% of revenues, with a particular focus on Middle East expansion. Sigachi offers over 82 high-purity excipients--ranging from various grades of MCC to advanced co-processed blends, and Pharma Coatings, addressing Pharmaceutical, Nutraceutical, and Specialty chemical needs. The company enjoys fruitful and long-lasting commercial relationships with over 500 customers in more than 65 countries. With a clear roadmap and strong execution capabilities, the company remains committed to delivering sustained financial performance and market leadership in the years ahead. About Sigachi Industries Ltd Founded in 1989, Sigachi Industries Limited is a global player in the pharmaceutical industry dedicated to pioneering advancements in Active Pharmaceutical Ingredients (APIs), Intermediates, Excipients, vitamin-mineral blends, and Operations and Management (O & M) services. The company's diverse product portfolio is manufactured in 5 multilocational facilities, viz. Telangana, Gujarat, and Karnataka. Aligned with its ethos of customer centricity, Sigachi established subsidiaries in UAE and USA to be closer to its clients and improve responsiveness. With a strong focus on innovation, quality, and regulatory compliance, we leverage cutting-edge technology and global expertise to develop high-value pharma, food and nutrition solutions that enhance healthcare outcomes. Committed to excellence, we continuously invest in Research and Development, ensuring the highest standards of quality and safety. With 36 years of industry experience, Sigachi is a trusted partner for pharmaceutical and nutraceutical companies spread across 65+ countries. Sigachi collaborates with healthcare partners, regulatory bodies, and global stakeholders to expand access to reliable, high-quality pharmaceutical ingredients. Sigachi ranks among the world's largest and most reputed suppliers for microcrystalline cellulose (MCC). Chaitanya Rapol Senior Manager - Marketing, Branding and Communications Sigachi Industries Limited Email: Forward-Looking Statements This document contains forward-looking statements related to Sigachi Industries' future growth prospects, business strategy, operational plans, and financial performance. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Factors such as regulatory changes, market conditions, supply chain dynamics, and global economic shifts may impact outcomes. Sigachi disclaims any obligation to update these statements, except as required by applicable law. (ADVERTORIAL DISCLAIMER: The above press release has been provided by VMPL. ANI will not be responsible in any way for the content of the same)
Hans India
5 days ago
- Business
- Hans India
Sigachi Industries reports 21 pc drop in net profit in Q4, revenue also declines
Sigachi Industries Limited has announced that the company's net profit fell by approximately 21.16 per cent, coming down to Rs 16.17 crore in Q4 from Rs 20.51 crore in the previous quarter. This dip comes alongside a decline in both revenue from operations and total income. Revenue from operations in Q4 stood at Rs 128.2 crore, down from Rs 139.41 crore in the previous quarter -- a fall of about 8.04 per cent. Total income also dropped to Rs 130.39 crore in Q4 compared to Rs 141.43 crore in Q3, marking a 7.81 per cent decrease. Despite the quarter-on-quarter (QoQ) decline, the company remains optimistic about its growth prospects. Commenting on the performance and outlook, Sigachi Industries Managing Director and CEO Amit Raj Sinha said: "FY25 has been a transformative year for Sigachi, marked by robust financial outcomes and strategic expansions across excipients and APIs." "With our Hyderabad API R&D centre going live in Q1 FY26, regulatory approvals flowing in, and global market penetration deepening, we are positioned for sustainable high-margin growth," he said. "Our 36-year legacy and diversified portfolio give us an unmatched advantage to scale operations globally while safeguarding profitability," he added. "The company is expanding its footprint beyond India, the US, and Europe by aggressively entering Latin America, Southeast Asia, and the Middle East through new distribution partnerships and turnkey O&M contracts," Sigachi said in its filing. Sigachi Industries, founded in 1989 and headquartered in Hyderabad, is a manufacturer in the field of pharma excipients, nutraceuticals, and food ingredients. The company is known for its global leadership in the production of microcrystalline cellulose (MCC), with manufacturing facilities in India and subsidiaries operating internationally. The company serves a broad spectrum of industries, including pharmaceuticals, food and beverages, nutraceuticals, and cosmetics.
Business Upturn
07-05-2025
- Business
- Business Upturn
Sigachi Industries receives Certificate of Suitability for Metformin Hydrochloride from EDQM
By Aman Shukla Published on May 7, 2025, 12:48 IST Sigachi Industries Limited has recently received the Certificate of Suitability (CEP) for Metformin Hydrochloride from the European Directorate for the Quality of Medicines & Health Care (EDQM) on May 5, 2025. This certification underscores Sigachi's adherence to quality standards, regulatory compliance, and its readiness for global markets. Metformin Hydrochloride, a common medication for managing type 2 diabetes, is projected to reach a market value of USD 386.91 million by 2030, growing at a compound annual growth rate (CAGR) of approximately 4.7%. Several Metformin-based Fixed Dose Combinations (FDCs) have already been approved by the U.S. Food and Drug Administration (USFDA), including products like Glucovance, Actoplus Met, Janumet, and others. These approvals highlight the recognized role of Metformin-based therapies in diabetes care. The CEP certification for Metformin Hydrochloride is in line with Sigachi's ongoing strategy to strengthen its presence in regulated markets, ensuring the company meets the European Union's stringent safety, efficacy, and Good Manufacturing Practice (GMP) requirements. Amit Raj Sinha, Managing Director and CEO of Sigachi Industries Limited, commented, 'This achievement aligns perfectly with our vision of expanding into highly regulated markets and strengthen our position in the global pharmaceutical industry. With the rising demand for Metformin-based therapies, Sigachi is committed to leveraging its R&D expertise and state-of-the-art facilities to deliver pharmaceutical solutions that meet international standards and address the dynamic needs of the healthcare sector.' Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Standard
28-04-2025
- Business
- Business Standard
Sigachi MENA FZCO signs MoU with Czech Republic-based Respilon
Sigachi MENA FZCO, a wholly owned subsidiary of Sigachi Industries, has signed a Memorandum of Understanding (MoU) with Respilon, an innovation-driven nanofiber R&D company headquartered in the Czech Republic. This partnership marks a significant milestone in Sigachi's strategy to expand into advanced drug delivery technologies. Sigachi and Respilon will collaborate to develop, manufacture, and commercialize drug delivery solutions based on Respilon's proprietary NUENEX nanofiber technology. The collaboration includes developing commercialization strategies for relevant APIs and formulations, leveraging nanofiber encapsulation technology.
Business Upturn
28-04-2025
- Business
- Business Upturn
Sigachi Industries arm signs MoU with Respilon Group for nanofiber-based drug delivery
By Aditya Bhagchandani Published on April 28, 2025, 12:15 IST Shares of Sigachi Industries Ltd could be in focus after the company announced a key strategic development on Monday. The company's wholly-owned subsidiary, Sigachi MENA FZCO, has signed a Memorandum of Understanding (MoU) with Czech Republic-based Respilon Group s.r.o. to collaborate on advancing nanofiber-based drug delivery technologies. Under the agreement, Sigachi and Respilon will jointly develop, manufacture, and commercialize drug delivery solutions based on Respilon's proprietary NUENEX® nanofiber technology. This partnership focuses on creating next-generation pharmaceutical delivery formats like the Invisible Patch and Powder-based formulations, which aim to improve therapeutic outcomes and elevate the patient experience through non-invasive, precision drug delivery. The MoU was signed on April 24, 2025, between Mr. Lijo Chacko, Managing Director of Sigachi MENA FZCO, and Mr. Roman Zima, Chief Business Officer of Respilon Group, during a formal ceremony. Key highlights of the collaboration: Focus on developing Invisible Patch and powder-based drug delivery systems. Commercialization strategies to be built around nanofiber encapsulation technology for APIs and formulations. Strengthening Sigachi's global presence in advanced drug delivery technologies. Commenting on the development, Mr. Amit Raj Sinha, Managing Director and CEO of Sigachi Industries, said, 'Partnering with Respilon aligns perfectly with our vision to deliver next-generation pharmaceutical solutions that improve therapeutic outcomes and elevate the patient experience.' Mr. Roman Zima of Respilon also expressed optimism, stating that Sigachi's deep industry expertise and global reach would accelerate the deployment of NUENEX® technology across pharmaceutical markets worldwide. About Sigachi Industries: Sigachi is a global player specializing in Active Pharmaceutical Ingredients (APIs), excipients, vitamin-mineral blends, and nutraceutical solutions, with manufacturing units across Telangana, Gujarat, and Karnataka. It operates in over 65 countries and has subsidiaries in the UAE and USA. About Respilon Group: Respilon, headquartered in the Czech Republic, specializes in nanofiber applications across health protection and pharmaceutical sectors, and operates in more than 46 countries. Disclaimer: This article contains forward-looking statements based on current expectations. Actual results may differ due to risks and uncertainties. Aditya Bhagchandani serves as the Senior Editor and Writer at Business Upturn, where he leads coverage across the Business, Finance, Corporate, and Stock Market segments. With a keen eye for detail and a commitment to journalistic integrity, he not only contributes insightful articles but also oversees editorial direction for the reporting team.
